0823 GMT - Japanese pharmaceutical stocks could gain on revived investor sentiment following recent U.S. pharma news, say Macquarie Capital analysts in a note. Pfizer's deal with the U.S. for a three-year tariff reprieve in exchange for lower drug prices was likely better than what investors had expected, prompting a rally in Japanese pharma growth names, Tony Ren and other analysts say. While value and high-dividend Japanese pharmaceutical stocks have outperformed year to date, growth names are likely to now catch up, the analysts say. Likely new Japanese leadership favoring loose monetary policy has also lifted Japanese equities as a whole, they add. Macquarie Capital's marquee buy picks are Chugai Pharmaceutical and Daiichi Sankyo, which have strong drug pipelines and could report higher-than-expected earnings. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

October 14, 2025 04:23 ET (08:23 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.